1585. The Annual Cost per Newly Virally-Suppressed Person with HIV in Those Starting Long-Acting Injectable Antiretroviral Therapy with Detectable Viremia in a Safety-Net Clinic in San Francisco

BACKGROUND: Long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) holds promise to effectively treat people with HIV (PWH) who are unable to achieve or maintain viral suppression on oral antiretroviral therapy (ART). METHODS: We employed standard micro-costing techniques to identify the resou...

Descripción completa

Detalles Bibliográficos
Autores principales: Marseille, Elliot, Walker, Ryan, Oskarsson, Jon, Grochowski, Janet, Hickey, Matt, Imbert, Elizabeth V, Szumowski, John, Koester, Kimberly, Smith, Mollie, Neilands, Tor, Johnson, Mallory, Sauceda, John, Montgomery, Elizabeth, McNulty, Moira, Colasanti, Jonathan, Christopoulos, Katerina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679146/
http://dx.doi.org/10.1093/ofid/ofad500.1420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679146/
http://dx.doi.org/10.1093/ofid/ofad500.1420

Ejemplares similares